EyePoint Pharmaceuticals Reports Incentive Grants Pursuant to NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company has granted new employees non-statutory stock options as incentive awards outside of the Company's 2023 Long-Term Incentive Plan under NASDAQ Listing Rule 5635(c)(4).

The Company granted two new employees stock options to purchase up to an aggregate of 43,000 shares of EyePoint Pharmaceuticals common stock. The stock options were granted on September 13, 2024. The awards were approved by the Compensation Committee and are granted as an incentive to each employee who enters into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $9.10 per share, the closing price of EyePoint Pharmaceuticals common stock on September 13, 2024. The options have a ten-year term and vest over four years, with 25% of the original share count vesting on the first anniversary of the respective employee's grant date and the remainder vesting in equal monthly installments over the following three years. The vesting of the options is contingent upon the employee's continued employment with EyePoint Pharmaceuticals through the applicable vesting dates.